BACKGROUND:Tenofovir disoproxil fumarate (tenofovir) has been associated with renal dysfunction in people infected with human immunodeficiency virus (HIV) receiving combination antiretroviral therapy. We reviewed data from an HIV preexposure prophylaxis trial to determine if tenofovir use was associated with changes in renal function in an HIV-uninfected population. METHODS: During the trial, 2413 HIV-uninfected people who inject drugs were randomized to receive tenofovir or placebo. We assessed the renal function of trial participants with the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations using t tests for cross-sectional analysis and linear regression for longitudinal analysis. RESULTS:Creatinine clearance and glomerular filtration rate (GFR) results were lower at 24, 36, 48, and 60 months in the tenofovir group compared with the placebo group. Results declined more in the tenofovir group than in the placebo group during follow-up using the Cockcroft-Gault (P < .001) and CKD-EPI (P = .007) equations, but not MDRD (P = .12). Creatinine clearance measured when study drug was stopped was lower in the tenofovir group than the placebo group (P < .001), but the difference resolved when tested a median of 20 months later (P = .12). CONCLUSIONS: We found small but significant decreases in cross-sectional measures of creatinine clearance and GFR in the tenofovir group compared with the placebo group and modest differences in downward trends in longitudinal analysis using the Cockcroft-Gault and CKD-EPI equations. These results suggest that with baseline assessments of renal function and routine monitoring of creatinine clearance during follow-up, tenofovir can be used safely for HIV preexposure prophylaxis. Clinical Trials Registration. NCT00119106. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND:Tenofovir disoproxil fumarate (tenofovir) has been associated with renal dysfunction in people infected with human immunodeficiency virus (HIV) receiving combination antiretroviral therapy. We reviewed data from an HIV preexposure prophylaxis trial to determine if tenofovir use was associated with changes in renal function in an HIV-uninfected population. METHODS: During the trial, 2413 HIV-uninfectedpeople who inject drugs were randomized to receive tenofovir or placebo. We assessed the renal function of trial participants with the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations using t tests for cross-sectional analysis and linear regression for longitudinal analysis. RESULTS:Creatinine clearance and glomerular filtration rate (GFR) results were lower at 24, 36, 48, and 60 months in the tenofovir group compared with the placebo group. Results declined more in the tenofovir group than in the placebo group during follow-up using the Cockcroft-Gault (P < .001) and CKD-EPI (P = .007) equations, but not MDRD (P = .12). Creatinine clearance measured when study drug was stopped was lower in the tenofovir group than the placebo group (P < .001), but the difference resolved when tested a median of 20 months later (P = .12). CONCLUSIONS: We found small but significant decreases in cross-sectional measures of creatinine clearance and GFR in the tenofovir group compared with the placebo group and modest differences in downward trends in longitudinal analysis using the Cockcroft-Gault and CKD-EPI equations. These results suggest that with baseline assessments of renal function and routine monitoring of creatinine clearance during follow-up, tenofovir can be used safely for HIV preexposure prophylaxis. Clinical Trials Registration. NCT00119106. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: David V Glidden; K Rivet Amico; Albert Y Liu; Sybil G Hosek; Peter L Anderson; Susan P Buchbinder; Vanessa McMahan; Kenneth H Mayer; Burns David; Mauro Schechter; Beatriz Grinsztejn; Juan Guanira; Robert M Grant Journal: Clin Infect Dis Date: 2016-01-20 Impact factor: 9.079
Authors: Kenneth K Mugwanya; Jared M Baeten; Christina Wyatt; Nelly R Mugo; Connie L Celum; Allan Ronald; John Kiarie; Elly Katabira; Renee Heffron Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Monica Gandhi; David V Glidden; Kenneth Mayer; Mauro Schechter; Susan Buchbinder; Beatriz Grinsztejn; Sybil Hosek; Martin Casapia; Juan Guanira; Linda-Gail Bekker; Alexander Louie; Howard Horng; Leslie Z Benet; Albert Liu; Robert M Grant Journal: Lancet HIV Date: 2016-08-31 Impact factor: 12.767
Authors: Monica Gandhi; Pamela M Murnane; Peter Bacchetti; Richard Elion; Michael A Kolber; Stephanie E Cohen; Howard Horng; Alexander Louie; Karen Kuncze; Catherine A Koss; Peter L Anderson; Susan Buchbinder; Albert Liu Journal: AIDS Date: 2017-10-23 Impact factor: 4.177
Authors: Connie Tien; Jason J Xu; Linda S Chan; Mimi Chang; Carolina Lim; Sue Lee; Brian Huh; Shuntaro Shinada; Ho S Bae; Tse-Ling Fong Journal: Dig Dis Sci Date: 2014-09-20 Impact factor: 3.199
Authors: Rabi Yacoub; Girish N Nadkarni; Damian Weikum; Ioannis Konstantinidis; Anna Boueilh; Robert M Grant; Kenneth K Mugwanya; Jared M Baeten; Christina M Wyatt Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt Journal: J Infect Dis Date: 2016-03-29 Impact factor: 5.226